Home Market News Micro Cap Stocks <!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>Cardlytics Shares Surge; Preview of Pre-Market Movers</title> </head> <body> Cardlytics Shares Surge; Preview of Pre-Market Movers

Cardlytics Shares Surge; Preview of Pre-Market Movers Cardlytics Shares Surge; Preview of Pre-Market Movers

<!DOCTYPE html>
<html lang= Cardlytics Shares Surge; Preview of Pre-Market Movers Cardlytics Shares Surge; Preview of Pre-Market Movers" title=" Cardlytics Shares Surge; Preview of Pre-Market Movers Cardlytics Shares Surge; Preview of Pre-Market Movers" />

Shares of Cardlytics, Inc. CDLX soared in today‚Äôs pre-market session post the company’s robust fourth-quarter earnings report.

Cardlytics exceeded expectations by posting adjusted earnings of 14 cents per share, surpassing the estimated 12 cents per share. The company’s optimistic outlook included first-quarter revenue projections of $70 million to $73 million, compared to the anticipated $66.46 million.

Witnessing a remarkable 36.6% surge, Cardlytics shares climbed to $11.18 in pre-market trading.

Let’s take a glance at some other stocks making notable moves in pre-market trading.


  • Fisker Inc. FSR witnessed a 31.3% increase to $0.2034 in pre-market trading. Fisker shares had seen a sharp decline of approximately 52% the previous day following reports hinting at potential bankruptcy proceedings.
  • Madrigal Pharmaceuticals, Inc. MDGL surged by 26.9% to $309.13 in pre-market trading post the company’s announcement of FDA approval for Rezdiffra in treating noncirrhotic NASH patients.
  • 2seventy bio, Inc. TSVT climbed 18.7% to $4.70 after releasing disappointing quarterly results on March 5.
  • American Vanguard Corporation AVD advanced 16% to $12.28 in pre-market trading following its Q4 financial performance.
  • Adial Pharmaceuticals, Inc. ADIL gained 14.4% to $1.99 pre-market.
  • Telesis Bio, Inc. TBIO climbed 11.6% to $0.5740 pre-market. The company disclosed select preliminary Q4 financial results on Feb. 26.
  • Brera Holdings PLC BREA saw an 11% rise to $1.61 in pre-market trading after a 6% dip the day before.
  • Aquestive Therapeutics, Inc. AQST rose 8.2% to $5.68 pre-market. Aquestive Therapeutics announced successful outcomes of Anaphylm meeting all designated primary and secondary pharmacokinetic targets.
  • Better Therapeutics, Inc BTTX advanced 7.7% to $0.0377 pre-market. Better Therapeutics experienced an 83% dip the prior day after revealing plans for strategic changes and Nasdaq delisting.


  • Kopin Corporation KOPN declined 14.6% to $1.87 pre-market following disappointing Q4 results.
  • Smartsheet Inc. SMAR fell 11.8% to $35.56 pre-market after reporting Q4 performance below expectations and issuing FY25 revenue guidance under estimates.
  • Adobe Inc. ADBE dipped 11.3% to $505.88 pre-market. While Adobe’s Q1 performance surpassed expectations, the company provided a cautious revenue outlook for the ongoing quarter.
  • Psyence Biomedical Ltd. PBM dropped 10.6% to $1.42 pre-market. Psyence Biomedical shares surged by 53% the previous day after the Indiana legislature approved funding for psilocybin clinical research trials.
  • Presto Automation Inc. PRST slipped 9.7% to $0.2720 pre-market, following a 34% rise the day before. The company announced a $1.2 million registered direct offering of 4.8 million shares at $0.25 each.
  • Kuke Music Holding Limited KUKE decreased by 9.1% to $2.26 pre-market after a 5% upturn on the prior day.
  • Alternus Clean Energy Inc ALCE saw an 8.7% decline to $0.4265 pre-market.
  • PagerDuty, Inc. PD dropped by 8.2% to $21.06 pre-market following its Q4 financial results and FY25 guidance below expectations.
  • Blink Charging Co. BLNK fell 7.6% to $3.17 pre-market post Q4 financial results.
  • Ulta Beauty, Inc. ULTA tumbled 6.6% to $ 527.99. The company reported Q4 results and issued FY24 revenue guidance below estimates. Additionally, Ulta Beauty’s board sanctioned a $2.0 billion stock buyback program.

Now Read This: Hibbett Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.